Longeveron Inc
LGVN0.785USD
+0.015+1.95%
終値 09/19, 16:00（ET）15分遅れの株価
11.86M時価総額
損失額直近12ヶ月PER
詳細情報 Longeveron Inc 企業名
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
企業情報
企業コードLGVN
会社名Longeveron Inc
上場日Feb 12, 2021
最高経営責任者「CEO」Mr. Wa'el Hashad
従業員数25
証券種類Ordinary Share
決算期末Feb 12
本社所在地1951 NW 7th Ave
都市MIAMI
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号33136
電話番号13053027158
ウェブサイトhttps://www.longeveron.com/
企業コードLGVN
上場日Feb 12, 2021
最高経営責任者「CEO」Mr. Wa'el Hashad
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
164.30K
+7.71%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
164.30K
+7.71%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
41.36K
+39.76%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+91.64%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
事業別USD
会社名
収益
比率
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
株主
更新時刻: Sun, Aug 31
更新時刻: Sun, Aug 31
株主統計
種類
株主統計
株主統計
比率
Lincoln Alternative Strategies LLC
6.09%
Armistice Capital LLC
3.50%
Lehr (Paul T)
1.71%
Hashad (Mohamed Wa'el Ahmed)
1.61%
Hare (Joshua M)
1.31%
他の
85.78%
株主統計
株主統計
比率
Lincoln Alternative Strategies LLC
6.09%
Armistice Capital LLC
3.50%
Lehr (Paul T)
1.71%
Hashad (Mohamed Wa'el Ahmed)
1.61%
Hare (Joshua M)
1.31%
他の
85.78%
種類
株主統計
比率
Individual Investor
8.73%
Corporation
6.09%
Hedge Fund
4.01%
Investment Advisor
1.57%
Investment Advisor/Hedge Fund
1.11%
Venture Capital
0.25%
Bank and Trust
0.02%
他の
78.21%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
2023Q1
64
155.94K
27.45%
-36.93K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Armistice Capital LLC
676.23K
5%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
229.86K
1.7%
+98.89K
+75.50%
Jun 23, 2025
Hashad (Mohamed Wa'el Ahmed)
144.05K
1.06%
-10.99K
-7.09%
Apr 21, 2025
Hare (Joshua M)
253.07K
1.87%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
162.52K
1.2%
-23.00K
-12.40%
May 30, 2025
Locklear (Lisa)
57.96K
0.43%
-6.21K
-9.68%
Apr 21, 2025
Agafonova (Nataliya)
57.46K
0.42%
-7.56K
-11.63%
Apr 21, 2025
The Vanguard Group, Inc.
144.27K
1.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
140.73K
1.04%
+7.13K
+5.33%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
日付
種類
比率
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
